Cik Cells
Urinary Bladder Carcinoma
Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05108077CT.gov Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | — | Unknown | — | — | — |
NCT02886897CT.gov A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cik Cells (this asset) | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | P1/2 | CC · 43 |
| Cis-Diamminedichloroplatinum Ii | G1 Therapeutics, Inc. | P3 | BBB |
| Trastuzumab | NKGen Biotech, Inc. | P2 | BB |
| Carboplatin | G1 Therapeutics, Inc. | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Pembrolizumab | Essen Biotech | P3 | BB |
| Vinblastine | University of Southern California | P3 | BB |
| Adriamycin | Toray Industries, Inc | P3 | BB |
| Methotrexate | University of Southern California | P3 | BB |
+42 more in the Urinary Bladder Carcinoma cohort
Other indications for Cik Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P3 | BB · 64 |
| Colorectal Cancer | — | P4 | B · 62 |
| Neoplasm | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cik Cells in Urinary Bladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cik-cells-urinary-bladder-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →